Cargando…
Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production
The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411908/ https://www.ncbi.nlm.nih.gov/pubmed/32635427 http://dx.doi.org/10.3390/plants9070842 |
_version_ | 1783568487689486336 |
---|---|
author | Shanmugaraj, Balamurugan I. Bulaon, Christine Joy Phoolcharoen, Waranyoo |
author_facet | Shanmugaraj, Balamurugan I. Bulaon, Christine Joy Phoolcharoen, Waranyoo |
author_sort | Shanmugaraj, Balamurugan |
collection | PubMed |
description | The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline. In this review, we consider the importance of a plant- based production system for recombinant protein production, and its potential to produce biopharmaceuticals is discussed. |
format | Online Article Text |
id | pubmed-7411908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74119082020-08-25 Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production Shanmugaraj, Balamurugan I. Bulaon, Christine Joy Phoolcharoen, Waranyoo Plants (Basel) Review The demand for recombinant proteins in terms of quality, quantity, and diversity is increasing steadily, which is attracting global attention for the development of new recombinant protein production technologies and the engineering of conventional established expression systems based on bacteria or mammalian cell cultures. Since the advancements of plant genetic engineering in the 1980s, plants have been used for the production of economically valuable, biologically active non-native proteins or biopharmaceuticals, the concept termed as plant molecular farming (PMF). PMF is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. The development and improvement of the transient expression system has significantly reduced the protein production timeline and greatly improved the protein yield in plants. The major factors that drive the plant-based platform towards potential competitors for the conventional expression system are cost-effectiveness, scalability, flexibility, versatility, and robustness of the system. Many biopharmaceuticals including recombinant vaccine antigens, monoclonal antibodies, and other commercially viable proteins are produced in plants, some of which are in the pre-clinical and clinical pipeline. In this review, we consider the importance of a plant- based production system for recombinant protein production, and its potential to produce biopharmaceuticals is discussed. MDPI 2020-07-04 /pmc/articles/PMC7411908/ /pubmed/32635427 http://dx.doi.org/10.3390/plants9070842 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Shanmugaraj, Balamurugan I. Bulaon, Christine Joy Phoolcharoen, Waranyoo Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production |
title | Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production |
title_full | Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production |
title_fullStr | Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production |
title_full_unstemmed | Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production |
title_short | Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production |
title_sort | plant molecular farming: a viable platform for recombinant biopharmaceutical production |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411908/ https://www.ncbi.nlm.nih.gov/pubmed/32635427 http://dx.doi.org/10.3390/plants9070842 |
work_keys_str_mv | AT shanmugarajbalamurugan plantmolecularfarmingaviableplatformforrecombinantbiopharmaceuticalproduction AT ibulaonchristinejoy plantmolecularfarmingaviableplatformforrecombinantbiopharmaceuticalproduction AT phoolcharoenwaranyoo plantmolecularfarmingaviableplatformforrecombinantbiopharmaceuticalproduction |